330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure

Shoichi Kuyama ,T Yamada,H Ishikawa,M Namba,Y Kataoka,H Yoshioka,K Sawa,A Tamiya,K Azuma,Y Yamanaka,H Kaneda,H Tanaka ,N Katakami ,A Hata ,T Yokoyama ,Y Fujisaka ,A Nakamura ,S Miura ,S Hara ,T Kurata

doi:10.1016/j.annonc.2022.10.369

330P A real-world multi-center prospective observational study of atezolizumab (Atezo) + bevacizumab (Bev) + carboplatin (CBDCA) + paclitaxel (PTX) (ABCP) in patients (pts) with advanced EGFR-mutated (EGFRm) NSCLC after EGFR-TKIs failure

Shoichi Kuyama , T Yamada + Show 18 more

https://doi.org/10.1016/j.annonc.2022.10.369

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Publication Date: Nov 1, 2022

Affiliation: Iwakuni Medical Center

#Advanced EGFR-mutated NSCLC #Clinical Outcomes In Pts + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Single-agent programmed death (PD)-1/PD-ligand (L) 1 inhibitors are known to have poor clinical outcomes in pts with advanced EGFRm NSCLC. Otherwise a subset analysis of the IMpower150 trial suggested the substantial efficacy of ABCP in the same pts’ population. We conducted a prospective observational study to evaluate the safety and effectiveness of ABCP in pts with advanced EGFRm NSCLC in a real world setting.

Full Text